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A series of chalcone and flavone derivatives (6a-d, 9a-f) based on 2,4-thiazolidinedione have been synthesized and 
evaluated for in vivo antihyperglycemic activity in sucrose loaded (SLM) and streptozotocin (STZ) induced diabetic animal 
models and also for antidyslipidemic activity in the triton model. Compounds 9d, 9e, and 9f exhibited potent blood glucose-
lowering activity in both SLM and STZ models. Compounds 6c, 6d, and 9c, 9e, and 9f showed moderate lipid-lowering 
activity. The selected most potent compounds 6d and 9e were also studied in db/db mice for both antihyperglycemic and 
antidyslipidemic activity. 
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Type-II diabetes is a common disease worldwide and 
is defined by the presence of fasting hyperglycemia, 
insulin resistance, and hyperinsulinemia. The global 
diabetes prevalence in 2019 is estimated to be 9.3% 
(463 million people), rising to 10.2% (578 million) by 
2030 and 10.9% (700 million) by 2045
 1
. The disease 
is often associated with obesity, dyslipidemia, and 
hypertension leading to cardiovascular risks
2
. The 
major chronic complications associated with untreated 
diabetes mellitus are neuropathy, retinopathy, 
nephropathy, and macrovasculopathy
3
. Therefore, it is 
important to maintain appropriate blood glucose 
levels, especially during the early stage of the disease. 
The therapy for type-II diabetes is often by a 
combination of diet, exercise, or pharmacological 
agents
4
. Thiazolidinediones generally referred to as 
glitazones are a new class of antidiabetic agents, 
identified as nuclear peroxisome proliferator activated 
receptor-gamma (PPAR-γ) ligands. 
They are chemically and functionally different 
from the other classes of oral antihyperglycemic 
agents such as sulfonylureas and metformin. They 
exert their effects by binding to PPAR-γ, which in 
turn, activates insulin-sensitive genes that regulate 
carbohydrate and lipid metabolism
5,6
. However, 
among the first of the glitazones introduced, 
Troglitazone was withdrawn from the market because 
of its hepatotoxicity
7
. Several other glitazones were 
discontinued from clinical development because of 
their structure and/or mechanism of action
8
. 
Pioglitazone and Rosiglitazone are available in the 
market with safety warnings
9
 (Figure 1). The 
associated problems with the existing glitazones 
prompt the development of safer new glitazones. 
Flavones and chalcones are polyphenolic 
compounds, isolated from natural products and 






















Chalcone and flavone derived propanolamines were 
synthesized as antihyperglycemic and antidyslipidemic 
agents
20-25
. The efforts towards the development of 
potent dual-acting hypoglycemic and hypolipidemic 
agents, the antioxidant property of flavonoids and 
chalcones attracted us, as oxidative stress plays an 
important role in diabetic patients leading to vascular 
complications
2,26
. The incorporation of a flavone or 
chalcone moiety as a lipophilic and antioxidant into 
—————— 
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glitazones may lead to a new set of compounds with 
enhanced activities. This led to the synthesis of 2,4-
thiazolidinedione derivatives with various spacers 
linked to the 7- and 3'-hydroxy position of the 
flavones and chalcones respectively and evaluation as 
antihyperglycemic and antidyslipidemic agents. 
 
Results and Discussion 
Chemistry 
The synthetic strategies used to synthesize the 
required compounds are outlined in Scheme I, Scheme II 
and Scheme III. 5-(4-Hydroxy-benzylidene)-2,4-
thiazolidinedione (3) has been synthesized by the 
condensation of commercially available 2,4-
thiazolidinedione (2) with 4-hydroxybenzaldehyde (1) 
using piperidine as the base in refluxing ethanol, 
according to a known procedure (Scheme I)
27
. 
Hydroxy chalcones (4a-b) and flavones (7a-e) 
were prepared according to literature procedures
20,23
. 
During the synthesis of flavones, Dowex-H
+
 in  
2-propanol has been used in place of AcOH-H2SO4, 
however, the rest of the procedure was similar as 
reported
28
. Flavones and chalcones thus obtained were 
alkylated at hydroxy groups with an excess of 
dibromoalkanes using K2CO3 and appropriate solvent 
at RT to afford 5a-d and 8a-f. Unwanted dimer was 
also obtained as a minor side product. The desired 
final products (6a-d and 9a-f) were prepared by 
reacting compound 3 with bromoalkoxy chalcones 
and flavones in dry dimethylformamide (DMF) in 
presence of K2CO3 at RT (Scheme II and Scheme III). 
 
Pharmacology 
All the synthesized compounds (6a-d and 9a-f) 
were evaluated for antihyperlipidemic activity in the 
triton model and antihyperglycemic activity in 
sucrose loaded (SLM) and streptozotocin (STZ) 
animal models. The potent selected compounds were 
also studied in db/db mice for both activities. 
Compound-23 (S001-469)
20-22
 is a chalcone based 
propanolamine, developed in our lab is a potent 
antidiabetic agent and used for comparison of the 
data. Metformin and Guggulipid were used as 
reference standards and the results are summarized in 
Table I. Methylenedioxy  compound  6d  reduced  the  
 
 
Scheme I — Synthesis of compound 3 
 
blood glucose levels by 13.4%, which is equipotent as 
the metformin (12.9%) in the SLM model. Chalcone 
derived thiazolidinediones (6a-c) have shown 
insignificant antidiabetic activity. Based on the 
antidiabetic activity of chalcone derivatives, while 
synthesizing flavone-based thiazolidinedione 
derivatives, the spacer was shortened from 
pentyl/butyl to ethyl/propyl, which is comparable to 
the chain length in the glitazone drugs and resulted in 
a significant increase in the activity. The 3',5'-
dibenzyloxy compound with two carbon-spacer (9a) 
was found to be inactive whereas the 3',4'-
dibenzyloxy compound (9b) significantly lowered the 
blood glucose by 26% in the SLM model. 3',4' and 
3',5'-dimethoxy, and 3',4',5'-trimethoxy compounds 
with three-carbon spacer (9d-f) have shown the best 
antihyperglycemic activity by lowering glucose levels 
by 28.8%, 29.3%, 13.6%, respectively. Compounds 
9d, 9e, and 9f have also significantly lowered the 
blood glucose levels in STZ induced diabetic animal 
model. Replacement of a three-carbon spacer with a 
two-carbon spacer resulted in the lowered 
antihyperglycemic activity as in trimethoxy 
compound (9c). In the triton model, chalcone and 
flavone derived thiazolidinedione derivatives showed 
moderate lipid-lowering activity. Compounds 6c, 9c, 
9e and 9f lowered the TC by 23%, 20%, 20% and 
28%, respectively. Compound 9c lowered the PL and 
TG by ~25% and 6d by ~20%.  
Based on the preliminary results from SLM, STZ, 
and triton models, selected compounds 6d and 9e 
along with compound 23 were evaluated in obese 
db/db mice for antihyperglycemic and 
antidyslipidemic activities. The antihyperglycemic 
activity results are summarized in Table II (Figure 2, 
Figure 3).   Compounds   6d   and   9e  significantly  
 
 
Figure 1 — Glitazone Drugs 




Table II — Antihyperglycemic activity of 6d, 9e, and  
23 in db/db mice 
S.No. Compd 
Fall of Blood Glucose Levels (%) 
STZ-S 
6 days 10 days 
1 6d 1.76 23.1 
2 9e 19.1 21.4 
3 23 +7.53 32.0 
4 Metformin 21.7 43.7 
STZ, streptozotocin 
lowered the blood glucose levels by 23.1% and 21.4% 
respectively after 10 days of dosing. 
Antihyperglycemic activity of 6d after 6 days of 
dosing is very small in comparison with 10 days of 
dosing. At the same time, compound 9e has almost 
reduced the blood glucose levels equally after 6 and 
10 days of dosing. Compound 23 showed poor 
activity after 6 days of dosing, but it significantly 
lowered the blood glucose levels by 32% in 
 
 




Scheme III — Synthesis of compounds 9(a-f) 
 






























S.No. Compd R n 
Fall in Blood Glucose Levels (%) 
Fall in Serum Lipid Profile (%) 
SLM 
STZ-S 
5h 24h TC PL TG 
1 6a 4-OCH3 2 NIL ND ND 4 14 31 
2 6b 4-OCH3 3 NIL ND ND 6 13 19 
3 6c 3,4-OCH2O- 2 0.13 ND ND 23 21 14 
4 6d 3,4-OCH2O- 3 13.4 11.8 7.18 13 20 20 
5 9a 3,5-OCH2Ph 1 NIL ND ND 15 15 18 
6 9b 3,4-OCH2Ph 1 26.0 ND NIL ND ND ND 
7 9c 3,4,5-OCH3 1 9.59 ND ND 20 25 26 
8 9d 3,5-OCH3 2 28.8 18.9 20.2 ND ND ND 
9 9e 3,4,5-OCH3 2 29.3 16.1 11.0 20 6 3 
10 9f 3,4-OCH3 2 13.6 18.7 13.6 28 14 21 
16 23 − − 21.1 ND 23 26 20 18 
17 Metformin 12.9 24.3 19.1  
18 Guggulipid  38 35 32 
ND, Not Determined; NIL, Insignificant activity. 
SLM, sucrose loaded model; STZ, streptozotocin; TC, total cholesterol; PL, phospholipids; TG, triglycerides 
 




comparison with metformin (43.7%) after 10 days of 
dosing.  
After 10 days of dosing, blood was withdrawn 
from db/db mice for analysis of serum lipid 
parameters, and the results are placed in Table III 
(Figure 4). Compound 23 lowered TC by 40.3% and 
raised the HDL level by 1.76%. All the compounds 
have shown an insignificant positive effect on HDL. 
Compounds 6d and 9e lowered the TG by 6.76% and 
19.1% respectively, while compound 23 has raised the 
TG by 7.44%. The lowering of TC by compounds 6d 
and 9e has been insignificant. In summary, methoxy 
substituted compounds are superior to the benzylated 
compounds and thiazolidinedione derivatives with 




Melting points were determined on a capillary 
melting point apparatus and are uncorrected. Reaction 
progress was monitored by TLC  and  performed  on 
Table III — Antidyslipidemic activity of 6d, 9e, and 23  
in db/db mice 
S.No. Compd 
Fall in Serum Lipid Profile (%) 
TC TG HDL 
1 6d +18.9 6.76 21.4 
2 9e 1.06 19.1 35.2 
3 23 40.3 +7.44 +1.76 
4 Metformin 28.5 11.1 24.7 
TC, total cholesterol; TG, triglycerides; HDL, high-density 
lipoprotein 
 
aluminum precoated GF254 TLC plates. TLC spots 





C NMR spectra were recorded 
in the indicated solvent on Bruker WM 200 MHz 
spectrometer with TMS as an internal standard. 
Infrared spectra were recorded in KBr on Perkin–
Elmer AC-1 spectrophotometer and FAB mass 
spectra on JEOL SX 102/DA 6000 mass 
spectrometer. Column chromatography was 
performed over silica gel (60-120 mesh). 
 
 




Figure 3 — Antihyperglycemic activity of compounds 6d, 9e, and 23 in db/db mice after 10 days of dosing 
 







A mixture of 4-hydroxybenzaldehyde, 1 (3 g, 24.6 
mmol), 2,4-thiazolidinedione, 2 (2.9 g, 24.8 mmol), 
and piperidine (2.5 mL) in methanol (100 mL) was 
refluxed for 18 h. The reaction mixture was poured 
into cold water and acidified with acetic acid. The 
separated solid was filtered, dried, and recrystallized 
from methanol to afford 3 (4.7 g, 86%); m.p. 296-




H NMR (200 MHz, DMSO-d6): δ 7.70 (s, 1H), 7.46 
(d, J = 8.6 Hz, 2H), 6.93 (d, J = 8.6 Hz, 2H); FAB-





Potassium carbonate (2.2 g, 15.8 mmol) was added 
to a stirred solution of 3'-hydroxy-4-methoxy-
chalcone, 4a (2 g, 7.87 mmol) in dry acetone (100 
mL) at RT. After the mixture was stirred for 30 min, 
1,4-dibromobutane (4.7 mL, 39.4 mmol) was added 
and the resulting mixture was stirred at RT for 12 h. 
The reaction mixture was filtered through celite and 
concentrated under reduced pressure. The residue was 
diluted with water and extracted with chloroform. The 
organic layer was washed with water, dried over 
anhydrous sodium sulphate, filtered, and concentrated 
in vacuo. The residue was purified by column 
chromatography eluting with ethyl acetate/hexane to 





H NMR (200 MHz, CDCl3): δ 7.79 (d, J = 15.6 
Hz, 1H), 7.60 (d, J = 8.7 Hz, 2H), 7.59 (d, J = 7.6 Hz, 
1H), 7.52 (d, J = 2.0 Hz, 1H), 7.39 (t, J = 7.8 Hz, 1H), 
7.38 (d, J = 15.6 Hz, 1H), 7.10 (dd, J = 8.1 Hz, 2.3 
Hz, 1H), 6.94 (d, J = 8.7 Hz, 2H), 4.08 (t, J = 5.7 Hz, 
2H), 3.86 (s, 3H), 3.50 (t, J = 6.3 Hz, 2H), 2.16-1.94 





Compound 5b was prepared from 3'-hydroxy-4-
methoxy-chalcone, 4a (2 g, 7.87 mmol), 1,5-
dibromopentane (5.4 mL, 39.4 mmol) and potassium 
carbonate (2.2 g, 15.8 mmol) in dry acetone (100 mL) 
using the procedure as described for 5a (2.7 g, 85%); 




H NMR (200 
MHz, CDCl3): δ 7.78 (d, J = 15.6 Hz, 1H), 7.60  
(d, J = 8.7 Hz, 2H), 7.58 (d, J= 7.4 Hz, 1H), 7.52  
(d, J = 2.2 Hz, 1H), 7.39 (t, J = 7.8 Hz, 1H), 7.39 (d,  
J = 15.6 Hz, 1H), 7.10 (dd, J = 8.0 Hz, 2.3 Hz, 1H), 
6.93 (d, J = 8.7 Hz, 2H), 4.04 (t, J = 6.2 Hz, 2H), 3.85 
(s, 3H), 3.44 (t, J = 6.7 Hz, 2H), 1.99-1.81 (m, 4H), 





Compound 5c was prepared from 3'-hydroxy-3,4-
methylenedioxy-chalcone, 4b (2.7 g, 10 mmol), 1,4-
dibromobutane (3.6 mL, 30 mmol) and potassium 
carbonate (2.76 g, 20 mmol) in dry acetone (100 mL) 
using the procedure as described for 5a (3.6 g, 89%); 




H NMR (200 
MHz, CDCl3): δ 7.73 (d, J = 15.6 Hz, 1H), 7.58 (d,  
J = 7.6 Hz, 1H), 7.51 (s, 1H), 7.39 (t, J = 7.8 Hz, 1H), 
7.34 (d, J = 15.6 Hz, 1H), 7.16 (s, 1H), 7.14-7.07  
(m, 2H), 6.84 (d, J = 7.9 Hz, 1H), 6.02 (s, 2H), 4.07 
(t, J = 5.6 Hz, 2H), 3.50 (t, J = 6.3 Hz, 2H), 2.16-1.94 






Compound 5d was prepared from 3'-hydroxy-3,4-
methylenedioxy-chalcone, 4b (2.7 g, 10 mmol), 1,5-
dibromopentane (4.1 mL, 30 mmol) and potassium 
carbonate (2.76 g, 20 mmol) in dry acetone (100 mL) 
using the procedure as described for 5a (2.7 g, 64%); 




H NMR (200 
MHz, CDCl3): δ 7.73 (d, J = 15.6 Hz, 1H), 7.57 (d,  
J = 7.6 Hz, 1H), 7.51 (d, J = 2.1 Hz, 1H), 7.39  
(t, J = 7.8 Hz, 1H), 7.34 (d, J = 15.6 Hz, 1H), 7.16  
(s, 1H), 7.14-7.10 (m, 2H), 6.02 (s, 2H), 4.05  
(t, J = 6.2 Hz, 2H), 3.50 (t, J = 6.7 Hz, 2H), 2.02-1.78 






Figure 4 — Antidyslipidemic activity of compounds 6d, 9e, and 23 in db/db mice 
 






A mixture of 3'-(4-bromo-butoxy)-4-methoxy-
chalcone, 5a (1.2 g, 3.1 mmol), 4-(thiazolidin-2,4-
dione-5-ylidinemethyl)-phenol, 3 (1 g, 4.62 mmol) 
and potassium carbonate (600 mg, 4.34 mmol) in dry 
dimethylformamide (80 mL) was stirred at RT for 8 h. 
The reaction mixture was filtered through celite and 
diluted with water. The aqueous layer was acidified 
with dilute hydrochloric acid, filtered, and extracted 
with chloroform. The organic layer was dried over 
anhydrous sodium sulphate, filtered, and 
concentrated. The crude product was purified by 
column chromatography eluting with ethyl 
acetate/hexane to yield 6a (800 mg, 49%); m.p. 186-




H NMR (200 MHz, DMSO-d6): δ 8.33 (s, 1H), 7.88 
(d, J = 8.7 Hz, 2H), 7.81 (d, J = 17.8 Hz, 1H), 7.75  
(s, 1H), 7.75(d, J = 7.7 Hz, 1H), 7.62 (s, 1H), 7.56  
(d, J = 8.8 Hz, 2H), 7.54 (t, J = 9.3 Hz, 1H), 7.49  
(d, J = 17.6 Hz, 1H), 7.25 (dd, J = 7.9 Hz, 2.1 Hz, 
1H), 7.12 (d, J = 8.7 Hz, 2H), 7.03 (d, J = 8.7 Hz, 
2H), 4.16 (bs, 4H), 3.84 (s, 3H), 1.94 (bs, 4H); FAB-





ylidinemethyl)-phenoxy]-pentyloxy}- chalcone, 6b 
A mixture of 3'-(5-bromo-pentyloxy)-4-methoxy-
chalcone, 5b (1.4 g, 3.47 mmol), 4-(thiazolidin-2,4-
dione-5-ylidinemethyl)-phenol, 3 (800 mg, 3.62 
mmol) and potassium carbonate (500 mg, 3.62 mmol) 
in dry dimethylformamide (80 mL) were reacted in a 
similar way as described for 6a to yield 6b (970 mg, 





H NMR (200 MHz, DMSO-d6): δ 7.75 
(d, J = 8.7 Hz, 2H), 7.67 (d, J = 17.1 Hz, 1H),  
7.63 (s, 1H), 7.61 (d, J = 7.7 Hz, 1H), 7.47 (s, 1H), 
7.43 (d, J = 9.1 Hz, 2H), 7.40 (t, J = 9.6 Hz, 1H), 7.36 
(d, J = 17.0 Hz, 1H), 7.11 (d, J = 8.1 Hz, 1H), 6.98 (d, 
J = 8.9 Hz, 2H), 6.92 (d, J = 8.7 Hz, 2H), 3.96  







A mixture of 3'-(4-bromo-butoxy)-3,4-
methylenedioxy-chalcone, 5c (3 g, 7.44 mmol), 4-
(thiazolidin-2,4-dione-5-ylidinemethyl)-phenol, 3 (1.8 
g, 8.14 mmol) and potassium carbonate (2.2 g, 16 
mmol) in dry dimethylformamide (125 mL) were 
reacted in a similar way as described for 6a to yield 





H NMR (200 MHz, DMSO-d6):  
δ 10.39 (s, 1H), 7.84 (s, 1H), 7.77 (s, 1H), 7.73 (d, J = 
16.9 Hz, 1H), 7.70 (d, J = 6.2 Hz, 1H), 7.62 (s, 1H), 
7.50 (d, J = 8.5 Hz, 2H), 7.48 (t, J = 8.4 Hz, 1H), 7.48 
(d, J = 16.7 Hz, 1H), 7.34 (d, J = 7.9 Hz, 1H), 7.23 (d, 
J = 6.5 Hz, 1H), 7.00 (d, J = 8.1 Hz, 1H), 6.94 (d, J = 
8.5 Hz, 2H), 6.12 (s, 2H), 4.10 (bs, 2H), 3.75 (bs, 2H), 






A mixture of 3'-(5-bromo-pentyloxy)-3,4-
methylenedioxy-chalcone, 5d (2.5 g, 5.9 mmol),  
4-(thiazolidin-2,4-dione-5-ylidinemethyl)-phenol, 3 
(1.6 g, 7.24 mmol) and potassium carbonate (2.2 g, 16 
mmol) in dry dimethylformamide (125 mL) were 
reacted in a similar way as described for 6a to yield 
6d (1.4 g, 42%); m.p. 159-161°C. IR (KBr): 3316, 




H NMR (200 MHz, DMSO-
d6): δ 10.41 (s, 1H), 7.85 (s, 1H), 7.74 (d, J = 16.7 Hz, 
1H), 7.73 (s, 1H), 7.71 (d, J = 5.4 Hz, 1H), 7.63  
(s, 1H), 7.50 (d, J = 8.9 Hz, 2H), 7.48 (t, J = 8.9 Hz, 
1H), 7.48 (d, J = 17.9 Hz, 1H), 7.36 (d, J = 7.9 Hz, 
1H), 7.23 (d, J = 5.9 Hz, 1H), 7.01 (d, J = 8.2 Hz, 
1H), 6.95 (d, J = 8.4 Hz, 2H), 6.13 (s, 2H), 4.08  
(t, J = 5.7 Hz, 2H), 3.70 (t, J = 6.6 Hz, 2H), 1.80-1.66 
(m, 4H), 1.49-1.46 (m, 2H); 
13
C NMR (200 MHz, 
DMSO-d6): δ 189.0, 167.9, 166.2, 160.5, 159.3, 
149.9, 148.5, 144.5, 139.5, 133.8, 132.9, 130.2, 129.6, 
126.4, 124.3, 121.2, 120.4, 119.6, 117.0, 116.7, 114.1, 
108.9, 107.1, 102.0, 67.8, 41.7, 28.5, 27.3, 23.0; FAB-





Compound 8a was prepared from 3',5'-
dibenzyloxy-7-hydroxy-flavone, 7a (2.25 g, 5 mmol), 
1,2-dibromoethane (5 mL, 58 mmol) and potassium 
carbonate (2.76 g, 20 mmol) in dry 
dimethylformamide (120 mL) using the procedure as 





H NMR (200 MHz, CDCl3):  
δ 8.13 (d, J = 8.8 Hz, 1H), 7.43-7.34 (m, 10H), 7.10 
(d, J = 2.1 Hz, 2H), 6.99 (dd, J = 8.8 Hz, 2.2 Hz, 1H), 
6.93 (d, J = 2.1 Hz, 1H), 6.76 (s, 1H), 6.69 (s, 1H), 
5.10 (s, 4H), 4.39 (t, J = 6.2 Hz, 2H), 3.69 (t, J = 6.2 





Compound 8b was prepared from 3',4'-dibenzyloxy-
7-hydroxy-flavone, 7b (2.3 g, 5.1 mmol), 1,2-




dibromoethane (1.7 mL, 20.4 mmol) and potassium 
carbonate (3.5 g, 25.5 mmol) in dry dimethyl–
formamide (90 mL) using the procedure as described 





H NMR (200 MHz, CDCl3): δ 8.12 (d, J = 8.8 
Hz, 1H), 7.50-7.32 (m, 12H), 7.01 (d, J = 9.1 Hz, 1H), 
6.92 (dd, J = 8.9 Hz, 2.2 Hz, 1H), 6.91 (s, 1H), 6.60  
(s, 1H), 5.24 (s, 4H), 4.39 (t, J = 6.2 Hz, 2H), 3.69  





Compound 8c was prepared from 7-hydroxy-3',4',5'-
trimethoxy-flavone, 7c (2.3 g, 7 mmol), 1,2-
dibromoethane (3 mL, 35 mmol) and potassium 
carbonate (2.9 g, 21 mmol) in dry dimethylformamide 
(120 mL) using the procedure as described for 5a (2.1 g, 





(200 MHz, CDCl3): δ 8.15 (d, J = 9.3 Hz, 1H), 7.10  
(s, 2H), 7.01 (d, J = 7.8 Hz, 1H), 6.99 (s, 1H), 6.71 (s, 
1H), 4.43 (t, J = 6.2 Hz, 2H), 3.96 (s, 6H), 3.93 (s, 3H), 





Compound 8d was prepared from 3',5'-dimethoxy-
7-hydroxy-flavone, 7d (1.1 g, 3.7 mmol), 1,3-
dibromopropane (1.9 mL, 18.5 mmol) and potassium 
carbonate (1.5 g, 11.1 mmol) in dry 
dimethylformamide (100 mL) using the procedure as 





H NMR (200 MHz, DMSO-d6): δ 
7.88 (d, J = 8.8 Hz, 1H), 7.35 (d, J = 2.1 Hz, 1H), 
7.17 (d, J = 2.1 Hz, 2H), 7.02 (dd, J = 8.9 Hz, 2.2 Hz, 
1H), 6.98 (s, 1H), 6.66 (s, 1H), 4.19 (t, J = 5.9 Hz, 
2H), 3.79 (s, 6H), 3.64 (t, J = 6.4 Hz, 2H), 2.26 (q, J = 





Compound 8e was prepared from 7-hydroxy-
3',4',5'-trimethoxy-flavone, 7c (3.3 g, 10 mmol), 1,3-
dibromopropane (3 mL, 30 mmol) and potassium 
carbonate (2.7 g, 20 mmol) in dry dimethylformamide 
(120 mL) using the procedure as described for 5a (3.1 




H NMR (200 MHz, CDCl3): δ 8.13 (d, J = 9.4 Hz, 
1H), 7.11 (s, 2H), 7.01-6.97 (m, 2H), 6.70 (s, 1H), 
4.25 (t, J = 5.8 Hz, 2H), 3.96 (s, 6H), 3.93 (s, 3H), 
3.64 (t, J = 6.3 Hz, 2H), 2.39 (q, J = 6.1 Hz, 2H); 





Compound 8f was prepared from 3',4'-dimethoxy-
7-hydroxy-flavone, 7e (3 g, 10 mmol), 1,3-
dibromopropane (4 mL, 39.2 mmol) and potassium 
carbonate (2.8 g, 20 mmol) in dry dimethylformamide 
(150 mL) using the procedure as described for 5a  




H NMR (200 MHz, CDCl3): δ 8.12 (d, J = 9.5 Hz, 
1H), 7.53 (dd, J = 8.5 Hz, 2.0 Hz, 1H), 7.36  
(d, J = 1.9 Hz, 1H), 6.99-6.95 (m, 3H), 6.68 (s, 1H), 
4.24 (t, J = 5.8 Hz, 2H), 3.98 (s, 3H), 3.96 (s, 3H), 
3.64 (t, J = 6.3 Hz, 2H), 2.39 (q, J = 6.1 Hz, 2H); 






A mixture of 7-(2-bromo-ethoxy)-3',5'-
dibenzyloxy-flavone, 8a (2 g, 3.6 mmol), 4-
(thiazolidin-2,4-dione-5-ylidinemethyl)-phenol, 3 (1.2 
g, 5.4 mmol) and potassium carbonate (740 mg, 5.4 
mmol) in dry dimethylformamide (120 mL) were 
reacted in a similar way as described for 6a to yield 
9a (600 mg, 24%); m.p. 267-269°C. IR (KBr): 3451, 




H NMR (200 MHz, DMSO-d6): 
δ 7.92 (d, J = 8.9 Hz, 1H), 7.73 (s, 1H), 7.55  
(d, J = 8.7 Hz, 2H), 7.49-7.32 (m, 12H), 7.29 (s, 1H), 
7.17 (s, 2H), 7.05 (d, J = 8.0 Hz, 1H), 7.03 (s, 1H), 
6.89 (s, 1H), 5.19 (s, 4H), 4.49 (bs, 2H), 4.47 (bs, 






A mixture of 7-(2-bromo-ethoxy)-3',4'-
dibenzyloxy-flavone, 8b (2 g, 3.6 mmol), 4-
(thiazolidin-2,4-dione-5-ylidinemethyl)-phenol, 3 (1.5 
g, 6.8 mmol) and potassium carbonate (1.4 g, 10 
mmol) in dry dimethylformamide (120 mL) were 
reacted in a similar way as described for 6a to yield 
9b (300 mg, 12%); m.p. 239-241°C. IR (KBr): 3446, 




H NMR (200 MHz, DMSO-d6): 
δ 10.35 (s, 1H), 7.87 (d, J = 8.9 Hz, 1H), 7.82 (s, 1H), 
7.69 (s, 1H), 7.64 (d, J = 8.6 Hz, 1H), 7.44  
(d, J = 8.3 Hz, 2H), 7.49-7.33 (m, 10H), 7.27  
(d, J = 2.6 Hz, 1H), 7.18 (d, J = 8.6 Hz, 1H), 6.97  
(dd, J = 8.8 Hz, 2.2 Hz, 1H), 6.88 (d, J = 8.5 Hz, 2H),  
6.87 (s, 1H), 5.23 (s, 2H), 5.21 (s, 2H), 4.37 (bs, 2H), 






A mixture of 7-(2-bromo-ethoxy)-3',4',5'-
trimethoxy-flavone, 8c (2 g, 4.6 mmol), 4-
(thiazolidin-2,4-dione-5-ylidinemethyl)-phenol, 3 (1.1 




g, 5 mmol) and potassium carbonate (2.5 g, 18 mmol) 
in dry dimethylformamide (150 mL) were reacted in a 
similar way as described for 6a to yield 9c (380 mg, 





H NMR (300 MHz, DMSO-d6): δ 10.37 
(s, 1H), 7.92 (d, J = 9.0 Hz, 1H), 7.86 (s, 1H), 7.49 (d, 
J = 9.0 Hz, 2H), 7.38 (d, J = 3.0 Hz, 1H), 7.36 (s, 2H) 
7.06 (s, 1H), 7.02 (dd, J = 9.0 Hz, 3.0 Hz, 1H), 6.91 
(d, J = 9.0 Hz, 2H), 4.41 (t, J = 4.5 Hz, 2H), 4.11  
(t, J = 4.5 Hz, 2H), 3.91 (s, 6H), 3.75 (s, 3H); FAB-






A mixture of 7-(3-bromo-propoxy)-3',5'-
dimethoxy-flavone, 8d (1 g, 2.4 mmol), 4-
(thiazolidin-2,4-dione-5-ylidinemethyl)-phenol, 3 
(600 mg, 2.7 mmol) and potassium carbonate (1.3 g, 
9.4 mmol) in dry dimethylformamide (80 mL) were 
reacted in a similar way as described for 6a to yield 
9d (220 mg, 16%); m.p. 229-230°C. IR (KBr): 3229, 




H NMR (300 MHz, DMSO-d6): 
δ 10.34 (s, 1H), 7.88 (d, J = 9.0 Hz, 1H), 7.79  
(s, 1H), 7.47 (d, J = 6.0 Hz, 2H), 7.30 (s, 1H), 7.20  
(s, 2H), 7.02 (s, 1H), 6.98 (d, J = 9.0 Hz, 1H), 6.91 
(d, J = 6.0 Hz, 2H), 6.71 (s, 2H), 4.20 (bs, 2H), 3.84 







A mixture of 7-(3-bromo-propoxy)-3',4',5'-
trimethoxy-flavone, 8e (3 g, 6.7 mmol), 4-
(thiazolidin-2,4-dione-5-ylidinemethyl)-phenol, 3 (1.7 
g, 7.7 mmol) and potassium carbonate (3.7 g, 27 
mmol) in dry dimethylformamide (150 mL) were 
reacted in a similar way as described for 6a to yield 
9e (900 mg, 23%); m.p. 203-204°C. IR (KBr): 3401, 




H NMR (300 MHz, DMSO-d6): 
δ 10.33 (s, 1H), 7.88 (d, J = 9.0 Hz, 1H), 7.77 (s, 1H), 
7.45 (d, J = 9.0 Hz, 2H), 7.32 (s, 1H), 7.28  
(d, J = 3.0 Hz, 1H), 7.03 (s, 1H), 6.96 (dd, J = 9.0 Hz, 
3.0 Hz, 1H), 6.93 (d, J = 9.0 Hz, 2H), 4.18 (t, J = 7.5 
Hz, 2H), 3.88 (s, 6H), 3.85 (t, J = 7.5 Hz, 2H),  
3.73 (s, 3H), 2.12-2.09 (m, 2H); 
13
C NMR (200  
MHz, DMSO-d6): δ 176.9, 168.0, 166.3, 163.3,  
162.4, 160.4, 157.7, 153.6, 140.9, 133.7, 132.9, 126.8, 
126.4, 124.2, 117.4, 117.1, 116.7, 115.0, 106.9, 104.2, 






A mixture of 7-(3-bromo-propoxy)-3',4'-
dimethoxy-flavone, 8f (2.5 g, 6 mmol), 4-(thiazolidin-
2,4-dione-5-ylidinemethyl)-phenol, 3 (1.4 g, 6.33 
mmol) and potassium carbonate (1 g, 7.24 mmol) in 
dry dimethylformamide (120 mL) were reacted in a 
similar way as described for 6a to yield 9f (600 mg, 





H NMR (200 MHz, DMSO-d6): δ 10.38 
(s, 1H), 7.91 (d, J = 8.8 Hz, 1H), 7.82 (s, 1H), 7.64  
(d, J = 9.0 Hz, 1H), 7.59 (s, 1H), 7.50 (d, J = 8.6 Hz, 
2H), 7.25 (d, J = 1.9 Hz, 1H), 7.12 (d, J = 8.6 Hz, 
1H), 6.99 (d, J = 8.8 Hz, 1H), 6.96 (s, 1H), 6.94  
(d, J = 8.5 Hz, 2H), 4.22 (bs, 4H), 3.90 (s, 3H), 3.87 





The biological evaluation of the synthesized 
compounds was carried out in sucrose loaded rat 
model for primary screening followed by a 
streptozotocin-induced beta-cell damaged diabetic rat 
model for antihyperglycemic and triton model for 
antidyslipidemic activities. The compounds which 
exhibited significant activity repeatedly in the STZ 
model were subjected to screen in db/db mice for 
antihyperglycemic and antidyslipidemic activity. 
 
Sucrose loaded rat model (SLM) 
Male albino rats of Charles Foster/Wistar strain of 
average body weight 160 ±20 g were selected for the 
study. The blood glucose level of each animal was 
checked by glucometer using glucostrips (Boehringer 
Mannheim) after 16 h starvation. Animals showing 
blood glucose levels between 60 to 80 mg/dL were 
divided into groups of five to six animals each. 
Animals of the experimental group were administered 
suspension of the desired synthetic compound orally 
(made in 1.0% gum acacia) at a dose of 100 mg/kg 
body weight. Animals of the control group were given 
an equal amount of 1.0% gum acacia. A sucrose load 
(10.0 g/kg) was given to each animal orally exactly 
after 30 min post administration of the test 
sample/vehicle. The blood glucose profile of each rat 
was again determined by glucometer at 30, 60, 90, 
and 120 min after administration of sucrose. Food but 
not water was withheld from the cages during the 
experiment. The quantitative glucose tolerance of 
each animal was calculated by the area under the 
curve (AUC) method (Prism Software). Comparing 




the AUC of experimental and control groups 
determined the percentage of antihyperglycemic 
activity. Statistical comparison was made by 
Dunnett's test. 
 
Sucrose-challenged Streptozotocin-induced diabetic 
model (STZ-S) 
Male albino rats of Sprague Dawley strain of 
average body weight 160±20 g were selected for the 
study. Streptozotocin
29
 (Sigma, USA) was dissolved in 
100 mM citrate buffer pH 4.5 and a calculated amount 
of the fresh solution was injected into overnight fasted 
rats (45 mg/kg) intraperitoneally. Blood glucose level 
was checked 48 h later by glucostrips and animals 
showing blood glucose values between 144 to  
270 mg/dL were included in the experiment and termed 
diabetic. The diabetic animals were divided into groups 
consisting of five to six animals each group. Animals 
of experimental groups were administered suspension 
of the desired test samples orally (made in 1.0% gum 
acacia) at a dose of 100 mg/kg body weight. Animals 
of the control group were given an equal amount of 
1.0% gum acacia. A sucrose load of 2.5 g/kg body 
weight was given after 30 minutes of compound 
administration. After 30 minutes of the post sucrose 
load, blood glucose level was again checked by 
glucostrips at 30, 60, 90, 120, 180, 240, 300 min, and 
24 h, respectively. Food but not water was withheld 
from the cages during the experimentation. Comparing 
the AUC of experimental and control groups 
determined the percent antihyperglycemic activity. 
Statistical comparison between groups was made by 
Student's 't' test 
 
Triton model 
Male Charles foster rats weighing 200-225 g were 
divided into control, dyslipidemic, and dyslipidemic plus 
drug-treated groups containing six animals in each 
group. Dyslipidemia was induced by the administration 
of Triton WR-1339 (200 mg/kg i.p.). All animals were 
maintained on a special pellet diet and water ad libitum. 
Compounds and the standard drug were macerated with 
0.2% aqueous gum acacia suspension. The suspension 
was fed orally at a dose of 100 mg/kg simultaneously 
with triton in the drug-treated group. The animals of the 
control group received the same amount of gum acacia 
by a similar route of administration. At the end of the 
experiment, after 18 h, blood was withdrawn from the 
retro-orbital plexus, and plasma was used for the assay 
of total cholesterol, phospholipid, and triglycerides using 
the assay kits as supplied by Roche
30-33
. 
Evaluation of antihyperglycemic and anti–
dyslipidemic activity in db/db mice 
C57BL/KsBom-db/db male mice of 12-18 weeks, 
40-50 g, bred in the animal house of CDRI, Lucknow 
were used in the experiments. The mice were housed 
in groups of 5 individuals in a room controlled for 
temperature (23 ± 2°C) and 12/12 hours light/dark 
cycle (lights on at 6.00 am). Body weight was 
measured daily from day 1 to day 10. All animals had 
free access to freshwater and normal chow except on 
the days of the postprandial protocol day 6 and during 
the overnight fast before the oral glucose tolerance 
test (OGTT) on day 10. Blood glucose was checked 
every morning up till day 5. On day 6 postprandial 
protocol was employed, in this method blood glucose 
was checked at −0.30 min and 0 h. Test compounds 
were given to the treatment group whereas the control 
group received only gum acacia (1.0%); the blood 
glucose was again checked at 1, 2, 3, 4, and 6 h after 
test compound treatment. Finally, on day l0 an OGTT 
was performed after overnight fasting. Blood glucose 
was measured at −0.30 min and test drugs were fed, 
blood glucose was again measured at 0.0 min post-
treatment, at this juncture, glucose solution was given 
at a dose of 3 gm/kg to all the groups including the 
control group; the profile of blood glucose was 
checked at 30 min, 60 min, 90 min, and 120 min after 
glucose administration. The quantitative glucose 
tolerance of each animal was calculated by the 
 area under the curve (AUC) method (Prism 
Software). Comparing the AUC of experimental and 
control groups determined the percentage of 
antihyperglycemic activity
34
. Blood was withdrawn 
from the retro-orbital plexus of the mice for the 
estimation of plasma triglyceride, cholesterol, HDL 






A new set of thiazolidinedione based chalcones and 
flavones were synthesized and evaluated in vivo in 
different animal models. The antihyperglycemic 
activity was assessed in SLM, STZ, and obese db/db 
mice and antidyslipidemic activity in the triton model. 
Compounds 6d, 9e, and 23 reduced the blood glucose 
levels significantly in db/db mice. In summary, 
methoxy substituted compounds are superior to the 
benzylated compounds, and thiazolidinedione 
derivatives with a three-carbon spacer are the best for 
antihyperglycemic activity. 
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